OverviewChartNewsTraderScreen

UBS Call 34.5 BAYN 20.06.2025/  CH1306629887  /

UBS Investment Bank
2024-11-15  9:20:01 AM Chg.0.000 Bid9:20:01 AM Ask- Underlying Strike price Expiration date Option type
0.001EUR 0.00% 0.001
Bid Size: 50,000		 -
Ask Size: -		 BAYER AG NA O.N. 34.50 EUR 2025-06-20 Call
TeleTrader 11-12 Bayer dips 12%, hits 20-year low after earnings report
TeleTrader 11-12 Bayer's sales in Q3 down 3.6% to €9.9 billion
TeleTrader 08-16 Bayer jumps 10% after Roundup court win
GlobeNewswire 08-02 Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting A...
GlobeNewswire 07-11 AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational...
GlobeNewswire 06-25 AskBio Initiates Recruitment to its Phase 2 Parkinson’s Disease Trial
GlobeNewswire 05-30 Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
GlobeNewswire 05-30 BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’...
GlobeNewswire 05-29 Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach
GlobeNewswire 05-28 Pairwise and Bayer Expand CRISPR Leafy Greens Market through Licensing Agreement
TeleTrader 05-14 Bayer's sales in Q1 at €13.7 billion, down 4.3%
GlobeNewswire 05-02 AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting...
GlobeNewswire 04-18 AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in conge...
GlobeNewswire 04-16 AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’...
GlobeNewswire 04-11 Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from...
GlobeNewswire 04-09 AskBio Names Mansuo Shannon Chief Scientific Officer
GlobeNewswire 03-25 BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rar...
GlobeNewswire 03-14 Bayer and Aignostics to collaborate on next generation precision oncology
GlobeNewswire 03-06 BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive tren...
TeleTrader 03-05 Bayer's Q4 sales at €11.9 billion
GlobeNewswire 03-04 BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
TeleTrader 03-04 Earnings preview: Bayer, Broadcom among those in calendar
GlobeNewswire 02-15 2Blades Delivers on Project with Bayer Crop Science to Combat Asian Soybean Rust
GlobeNewswire 02-13 Corporate Alignment with Climate Goals Under Scrutiny: LyondellBasell & Bayer demonstrate good pract...
GlobeNewswire 02-13 First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure